Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
暂无分享,去创建一个
[1] T. Chou,et al. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. , 1987, Cancer research.
[2] J. Bertino,et al. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. , 1987, Cancer research.
[3] J. Bertino,et al. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. , 1984, Biochemical pharmacology.
[4] B. Lathan,et al. Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone. , 1984, Cancer treatment reports.
[5] J. Mulder,et al. 5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling. , 1981, European journal of cancer & clinical oncology.
[6] H. Hansen,et al. The Variability of Individual Tolerance to Methotrexate in Cancer Patients , 1971, British Journal of Cancer.
[7] D. Dykes,et al. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia. , 1987, NCI monographs : a publication of the National Cancer Institute.
[8] B. Leyland-Jones,et al. Biochemical modulation: application of laboratory models to the clinic. , 1986, Cancer treatment reports.
[9] D. W. Fry,et al. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. , 1984, Advances in enzyme regulation.